QuantuMDx has introduced a rapid, polymerase chain reaction (PCR) diagnostic system, Q-POC, for use in point of care settings to detect Covid-19.

The portable system and its first test, named Q-POC SARS-CoV-2 assay, have received CE-IVD mark for use in Europe.

A user-friendly, accessible and inexpensive device, the PCR system delivers quick, molecular diagnostic testing with results offered in nearly 30 minutes.

QuantuMDx noted that the device compresses a complete molecular diagnostic laboratory into one system.

Meant for front-line healthcare workers, Q-POC can also be used in various settings, which include emergency rooms, ICU, birthing centres, clinics and pharmacies.

The SARS-CoV-2 assay is placed within a sealed, single-use test cassette that ensures safety and easy usage as well as eradicating contamination risk, the company noted.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In addition, on-board reagents are lyophilised to facilitate storage at room temperature, shipping convenience and extended shelf life.

The assay is designed with the latest sequence information to guarantee full coverage of all known SARS-CoV-2 sequences.

An analysis to test the clinical performance of the Q-POC SARS-CoV-2 assay was conducted at St George’s, University of London, UK.

The assay had a sensitivity and specificity of 96.9% and 98.3%, respectively, with no cross-reactivity with common commensal or potentially interfering organisms, the development and assessment of rapid technology (DART) study found.

During the study, the new assay was compared to tests that are currently available for use.

QuantuMDx chief executive Jonathan O’Halloran said: “Q-POC represents a new class of molecular diagnostic device: it’s fast, battery-operated, can multiplex and is so simple to operate that anyone can be trained to use it.

“Working with our British manufacturing partner, Cogent Technology, and Singapore-based, Univac, we have scaled manufacturing to ensure the security of supply for our customers and we are excited to be open for business.”

In March last year, QuantuMDx received $22m (£16m) funding from the UK Government to develop the Q-POC system and disposable cassettes for quick, point of care testing for Covid-19 in high and low-resource settings.

The fund included $4.4m (£3.2m) to manufacture QuantuMDx’ lab-based Covid-19 test, which is being commercialised.